How do I schedule Melanotan I alongside my existing stack?

Melanotan I's schedule is built around its ~2-30 days (implant); ~30 min SubQ pharmacokinetics and 1x daily during loading; less frequent maintenance dosing pattern. Coordination with other peptides depends on route compatibility (multiple SubQ compounds can share an injection where chemistry permits), receptor overlap (avoid stacking compounds engaging the same primary receptor), and operational convenience. Add one new compound at a time with 2 weeks of isolated dosing before stacking.

Should I cycle Melanotan I?

Standard cycle for Melanotan I is 8–12 weeks of 1x daily during loading; less frequent maintenance 0.5-1 mg dosing via subq/implant (approved formulation), followed by a 4 week complete off-period. The off-period is calibrated to Melanotan I's ~2-30 days (implant); ~30 min SubQ half-life and to typical receptor downregulation timelines. Continuous indefinite dosing does not show additional clinical benefit in the published literature and increases cumulative downregulation risk.

How long until I see results from Melanotan I?

Acute effects from Melanotan I appear within hours of dosing for receptor-level changes. scheduling and cycle endpoints accumulate across 4–8 weeks; the typical 8–12 week cycle is calibrated to allow the full response window. Single-week evaluations consistently underestimate the response trajectory.

What class of compound is Melanotan I?

Melanotan I is classified as a α-MSH analogue (long-acting). Within this class, alternative names and analogues include Afamelanotide, Scenesse, MT-I. The class-level pharmacology shapes both the clinical applications and the safety profile; the protocol / scheduling / cycling literature treats Melanotan I alongside its class peers when evaluating relative merits.

Home/ Compounds/ Melanotan I

Melanotan I

Protocol

For protocol designers building Melanotan I into a multi-compound regimen, the practical questions are pharmacokinetic compatibility, route compatibility, receptor non-overlap, and operational scheduling around real-world constraints (travel, meals, training). The 0.5-1 mg 1x daily during loading; less frequent maintenance dose at ~2-30 days (implant); ~30 min SubQ half-life informs which scheduling pattern fits.

Protocol / Scheduling / Cycling Applications

Wash-OutProtocol CalendarDaily TimingTravel ConsiderationsLoading Phase

Key Takeaways

Scheduling lens: Melanotan I's ~2-30 days (implant); ~30 min SubQ half-life via subq/implant (approved formulation) places it in the multi-daily-dosing bucket.
Mechanism: Selective melanocortin-1 receptor (MC1R) agonist.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. Schedule design for Melanotan I starts from the pharmacokinetic constraints implied by this mechanism and the published half-life. The subsections below address daily and weekly timing, cycle length and off-period planning, stack scheduling with other compounds, and travel-and-continuity considerations.

Daily and weekly timing

Melanotan I with a ~2-30 days (implant); ~30 min SubQ half-life pharmacokinetic profile sits in the weekly-dosing-friendly bucket. The schedule is best built around either 1x daily during loading; less frequent maintenance, with consistency mattering more than the absolute clock time of any single dose.

Stack scheduling with other compounds

When Melanotan I is part of a multi-compound stack, the scheduling question becomes how to time its dose relative to the others. Multiple subcutaneous compounds can be combined in a single injection where compatible, or staggered through the day where pharmacokinetics differ meaningfully. The pragmatic schedule reflects both pharmacokinetic constraints and the user's operational reality.

Cycle length and off-cycle planning

Standard Melanotan I cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Protocol / Scheduling / Cycling Applications

Daily Timing

Schedule design for Melanotan I in daily timing starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Stack Scheduling

The most-asked scheduling question for Melanotan I in stack scheduling is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Wash-Out

For wash-out scheduling, Melanotan I is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Loading Phase

Schedule design for Melanotan I in loading phase starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	0.5-1 mg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	1.5-1 mg	4–6 weeks initial cycle
Protocol focus	SubQ	0.5-1 mg	1x daily during loading; less frequent maintenance
Maintenance phase	SubQ	1.5-1 mg	Ongoing with periodic pauses

Dose timing for Melanotan I is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Melanotan I stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Melanotan I + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Melanotan I's mechanism in protocol / scheduling / cycling protocols.
Melanotan I + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Melanotan I's mechanism in protocol / scheduling / cycling protocols.
Melanotan I + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Melanotan I's mechanism in protocol / scheduling / cycling protocols.
Melanotan I + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Melanotan I's mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list FDA: Approved (Scenesse implant for EPP) Research: Phase III in EPP; off-label tanning use

Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history.

Lens-specific safety considerations for protocol / scheduling / cycling use of Melanotan I: Hyperpigmentation (intended). Nausea on initial doses. Watch for new/changing moles. Avoid in personal/family melanoma history. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

Afamelanotide in erythropoietic protoporphyria

PMID 26177253

Melanotan I vs Related Peptides

Compound	Profile	Onset	Best For
Melanotan I	α-MSH analogue (long-acting)	~2-30 days (implant); ~30 min SubQ	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Cycle length and off-cycle period?

Standard cycle for Melanotan I is 8–12 weeks on, 4 weeks off. Longer cycles produce diminishing returns and increased downregulation risk; shorter cycles undershoot the response window. The 4-week off-period is functionally required for receptor reset rather than optional.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

Daily timing for Melanotan I?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

What is the mechanism of action of Melanotan I?

Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. For scheduling and cycle applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Selective melanocortin-1 receptor (MC1R) agonist. The protocol / scheduling / cycling interpretation focuses on the pathway-level detail rather than on any single high-level summary.

What is Melanotan I?

Melanotan I (also known as Afamelanotide / Scenesse) is a 13-residue α-msh analogue (long-acting) with a molecular weight of 1646 Da and a plasma half-life of ~2-30 days (implant); ~30 min SubQ. Selective melanocortin-1 receptor (MC1R) agonist. Increases eumelanin production in melanocytes. Provides photoprotection. Lacks the MC4R-mediated central effects (libido, appetite, sexual response) of Melanotan II. The compound is studied primarily in the protocol / scheduling / cycling domain for the applications outlined above.

Clinical Protocol

Start a Melanotan I Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Melanotan I and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 1646 Da
Sequence length: 13 aa
Half-life: ~2-30 days (implant); ~30 min SubQ
WADA: Not on prohibited list
FDA: Approved (Scenesse implant for EPP)
Research: Phase III in EPP; off-label tanning use

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Melanotan I unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Melanotan I

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised